Events
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
2
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
3
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
4
FDA Fast Tracks Onvansertib for First-Line RAS-Mutated mCRC
5
